Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
93.94
+1.17 (+1.27%)
Streaming Delayed Price
Updated: 10:27 AM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomarin Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
September 28, 2023
Via
Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
What 16 Analyst Ratings Have To Say About Biomarin Pharmaceutical
September 13, 2023
Via
Benzinga
Earnings Outlook For Biomarin Pharmaceutical
July 28, 2023
Via
Benzinga
4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
September 23, 2023
A nearly 15% decline in the growth-driven Nasdaq Composite from its record high is a blessing in disguise for opportunistic long-term investors.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
September 18, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
September 15, 2023
Via
Benzinga
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
July 27, 2023
Via
Benzinga
What 13 Analyst Ratings Have To Say About Biomarin Pharmaceutical
July 03, 2023
Via
Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
September 15, 2023
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.
Via
Investor's Business Daily
Exposures
Product Safety
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
September 02, 2023
The innovation-fueled Nasdaq Composite remains 13% below its all-time high, which means bargains can still be found.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
4 Unforgettable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
August 12, 2023
With the growth-driven Nasdaq Composite still 14% below its record-closing high, deals abound.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Biomarin's Q2 Beat Street View, Raises Voxzogo Annual Guidance Driven By Global Demand
August 01, 2023
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) reported a Q2 adjusted EPS of $0.54, higher than $0.41 a year ago and beating the
Via
Benzinga
3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True
July 06, 2023
These high return biotech stocks offer tremendous upside ahead and are likely to soar on the back of several growth drivers
Via
InvestorPlace
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
June 14, 2023
Via
Benzinga
Earnings Scheduled For July 31, 2023
July 31, 2023
Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
July 27, 2023
Via
Benzinga
Is BioMarin Ready To Rebound After FDA Approval Of Roctavian?
July 06, 2023
BioMarin gets FDA approval for Roctavian and earned an upgrade because of it; shares may be ready to rebound but there are still hurdles.
Via
MarketBeat
Exposures
Product Safety
BioMarin Presents ~20% Upside Amid Voxzogo's Success and Slow Roctavian Uptake, Analyst Says
July 05, 2023
BMO Capital Markets has upgraded BioMarin Pharmaceutical Inc (NASDAQ: BMRN) to Outperform from Market Perform, and the price target remains at $102,
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
July 05, 2023
Via
Benzinga
BioMarin's Roctavian US Launch: Focus on Commercial Strategy Amid EU Failures, Analyst Points Out
June 30, 2023
On Thursday, The FDA approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults
Via
Benzinga
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories
June 30, 2023
New York Post
Via
Benzinga
BioMarin's Delayed Roctavian Scores FDA Nod As First Hemophilia A Gene Therapy In US
June 30, 2023
The FDA approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency...
Via
Benzinga
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
June 30, 2023
Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical...
Via
Benzinga
3 Biotech Stocks to Buy With Explosive Upside Potential
June 22, 2023
These three biotech stocks with high upside potential also display some significant risk, but less so than many of their small-cap peers.
Via
InvestorPlace
NASDAQ: BMRN Long Term Investor Notice: Lawsuit Against Directors at BioMarin Pharmaceutical Inc. Filed
June 20, 2023
San Diego, CA -- (SBWIRE) -- 06/20/2023 -- The Shareholders Foundation announced that an investor in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) filed a lawsuit against certain directors of...
Via
SBWire
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
June 07, 2023
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
May 26, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 25, 2023
Via
Benzinga
3 Biotech Stocks With Blockbuster Potential
May 24, 2023
Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.